T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Pipeline Review, H1 2018 - ResearchAndMarkets.com
Jun. 05, 2018
DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The "T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.
T Lymphocyte Activation Antigen CD80 - Pipeline Review, H1 2018, outlays comprehensive information on the T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics development with respective active and dormant or discontinued projects.
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 2, 4 and 2 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Musculoskeletal Disorders, Dermatology, Genito Urinary System And Sex Hormones, Metabolic Disorders, Ophthalmology and Respiratory which include indications Rheumatoid Arthritis, Autoimmune Disorders, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alopecia, Breast Cancer, Dermatomyositis, Diffuse Large B-Cell Lymphoma, Focal Segmental Glomerulosclerosis (FSGS), Graft Versus Host Disease (GVHD), Granulomatosis with Polyangiitis (Wegener Polyangiitis), Hepatocellular Carcinoma, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Juvenile Rheumatoid Arthritis, Lupus Nephritis, Myasthenia Gravis, Nephrotic Syndrome, Polyarticular Juvenile Idiopathic Arthritis (PJIA), Polymyositis/Idiopathic Inflammatory Myopathy, Renal Cell Carcinoma, Sicca Syndrome (Sjogren), Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Transplant Rejection, Type 1 Diabetes (Juvenile Diabetes), Uveitis and Vitiligo.
Key Topics Covered:
For more information about this report visit https://www.researchandmarkets.com/research/d2h59k/t_lymphocyte?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180605006717/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Lymphoma Drugs
INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/05/2018 04:51 PM/DISC: 06/05/2018 04:51 PM